Fighting an Invisible Enemy: Beginning a New Chapter in the COVID‑19 Era

Farahnak Assadi


Editorial Comment, The Coronavirus disease (COVID-19) pandemic has disproportionately impacted communities of color and particularly Black and Hispanic individuals.


COVID-19; Invisible Enemy; SARS-C0V-2

Full Text:



Zohner YE. Morris JS. COVID-TRACK: World and USA

SARS-CoV-2 testing and COVID-19 tracking. BioData Min


Khatri UG, Pizzicato LN, Viner K, Bobyock E. Sun M,

Meisel ZF, et al. Racial/ethic disparities in uninternational

fatal and non-fatal emergency medical services-attended opiod

overdoses durining the COVID-19 pandemic in Philadelphia.

JAMA Netw Open 2021;4:e2034878.

Gundlapalli AV, Salerno RM, Brooks JT, Averhoff F,

Peterson LR, McDonald LC, et al. SARS-CoV-2 serologic

assay needs for the next phase of the US COVID-19 pandemic

response. Open Forum Infect Dis 2020;8:ofaa555.

Oliveira EMN, Carvalho ARB, Silva JSE, Sousa Neto AR,

Moura MEB, Freitas DRJ, et al. Analysis of scientific

production on the new coronavirus (COVID-19): A bibliometric

analysis. Sao Paulo Med J 2021;S1516-31802021005002103.

doi: 10.1590/1516-3180.2020.0449.R1.01102020. Online

ahead of print.

Razizadeh M, Nikfar M, Liu Y. Small molecule to destabilize the

ACE2-RBD complex: A molecular dynamic study for potential

COVID-19 therapeutics. ChemRxiv 2020. doi: 10.26434/


Pourseif MM, Parvizpour S, Jafari B, Dehghani J, Naghill B,

Omid YB. A domain-based vaccine construct against

SARS-CoV-2, the causative agent of COVID-19 pandemic:

Development of self‑ampliflying mRNA and peptide vaccines. Bioimpacts 2021;1165-84.

Kim JH, Marks F, ClemensJD. Looking beyond COVID-19 vaccine

phase 3 trials. Nat Med 2021.


Ellis P, Somogyvarti F, Virok DP, Noseda M, McLean GR.

Decoding Covid-19 with SARS-CoV-2 genome. Curr Genet Med

Rep 2021;1-12. doi: 10.1007/s40142-020-00197-5. Online ahead

of print.